title: Omalizumab in the management of steroid dependent allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis.
abstract: Allergic bronchopulmonary aspergillosis [ABPA] complicates cystic fibrosis in around 10% of teenagers. Systemic corticosteroids are the mainstay of treatment but with on-going use are associated with significant side effects prompting consideration of steroid sparing therapies. The clinical courses over ten years of two children with CF complicated by steroid dependent chronic ABPA and its successful treatment with monthly omalizumab are reported.
authors.affiliation: Discipline of Paediatrics and Child Health, Sydney Medical School, University of Sydney, Sydney, Australia.
authors.forename: Rachel
authors.initials: R
authors.lastname: Wong
authors.forename: Melanie
authors.initials: M
authors.lastname: Wong
authors.forename: Paul D
authors.initials: PD
authors.lastname: Robinson
authors.forename: Dominic A
authors.initials: DA
authors.lastname: Fitzgerald
mesh_terms: D000293:Adolescent; D018926:Anti-Allergic Agents / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001229:Aspergillosis, Allergic Bronchopulmonary / Q000188:drug therapy* / Q000209:etiology; D003550:Cystic Fibrosis / Q000150:complications / Q000188:drug therapy; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D000069444:Omalizumab; D012008:Recurrence
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; D000069444:Omalizumab